Cephalosporin resistance, tolerance, and approaches to improve their activities
© 2023. The Author(s), under exclusive licence to the Japan Antibiotics Research Association..
Cephalosporins comprise a β-lactam antibiotic class whose first members were discovered in 1945 from the fungus Cephalosporium acremonium. Their clinical use for Gram-negative bacterial infections is widespread due to their ability to traverse outer membranes through porins to gain access to the periplasm and disrupt peptidoglycan synthesis. More recent members of the cephalosporin class are administered as last resort treatments for complicated urinary tract infections, MRSA, and other multi-drug resistant pathogens, such as Neisseria gonorrhoeae. Unfortunately, there has been a global increase in cephalosporin-resistant strains, heteroresistance to this drug class has been a topic of increasing concern, and tolerance and persistence are recognized as potential causes of cephalosporin treatment failure. In this review, we summarize the cephalosporin antibiotic class from discovery to their mechanisms of action, and discuss the causes of cephalosporin treatment failure, which include resistance, tolerance, and phenomena when those qualities are exhibited by only small subpopulations of bacterial cultures (heteroresistance and persistence). Further, we discuss how recent efforts with cephalosporin conjugates and combination treatments aim to reinvigorate this antibiotic class.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
The Journal of antibiotics - 77(2024), 3 vom: 19. März, Seite 135-146 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Araten, Alison H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 28.02.2024 Date Revised 16.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41429-023-00687-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366052322 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366052322 | ||
| 003 | DE-627 | ||
| 005 | 20240416232412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41429-023-00687-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM366052322 | ||
| 035 | |a (NLM)38114565 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Araten, Alison H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cephalosporin resistance, tolerance, and approaches to improve their activities |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to the Japan Antibiotics Research Association. | ||
| 520 | |a Cephalosporins comprise a β-lactam antibiotic class whose first members were discovered in 1945 from the fungus Cephalosporium acremonium. Their clinical use for Gram-negative bacterial infections is widespread due to their ability to traverse outer membranes through porins to gain access to the periplasm and disrupt peptidoglycan synthesis. More recent members of the cephalosporin class are administered as last resort treatments for complicated urinary tract infections, MRSA, and other multi-drug resistant pathogens, such as Neisseria gonorrhoeae. Unfortunately, there has been a global increase in cephalosporin-resistant strains, heteroresistance to this drug class has been a topic of increasing concern, and tolerance and persistence are recognized as potential causes of cephalosporin treatment failure. In this review, we summarize the cephalosporin antibiotic class from discovery to their mechanisms of action, and discuss the causes of cephalosporin treatment failure, which include resistance, tolerance, and phenomena when those qualities are exhibited by only small subpopulations of bacterial cultures (heteroresistance and persistence). Further, we discuss how recent efforts with cephalosporin conjugates and combination treatments aim to reinvigorate this antibiotic class | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Cephalosporins |2 NLM | |
| 650 | 7 | |a Monobactams |2 NLM | |
| 700 | 1 | |a Brooks, Rachel S |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Sarah D W |e verfasserin |4 aut | |
| 700 | 1 | |a Esguerra, Laura L |e verfasserin |4 aut | |
| 700 | 1 | |a Savchyn, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Emily J |e verfasserin |4 aut | |
| 700 | 1 | |a Leon, Gabrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Sniezek, Katherine J |e verfasserin |4 aut | |
| 700 | 1 | |a Brynildsen, Mark P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of antibiotics |d 1953 |g 77(2024), 3 vom: 19. März, Seite 135-146 |w (DE-627)NLM000017655 |x 1881-1469 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2024 |g number:3 |g day:19 |g month:03 |g pages:135-146 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41429-023-00687-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2024 |e 3 |b 19 |c 03 |h 135-146 | ||